Simulations Plus Releases ADMET Predictor ® 13

Simulations Plus (SLP) has launched ADMET Predictor 13, an upgraded machine learning platform for drug discovery, featuring enhanced high-throughput PBPK simulations, improved AI-driven drug design, and more accurate ADMET models. The new version offers enterprise-ready automation with extended APIs and Python scripting, aiming to streamline R&D workflows and provide more precise predictions for clients; however, the company's forward-looking statements caution that actual results may differ materially due to various risk factors including market conditions and the integration of business units.

Analysis

Simulations Plus, Inc. (Nasdaq: SLP) has launched ADMET Predictor® 13, an upgraded version of its core machine learning platform for drug discovery, indicating a continued focus on technological advancement within the biopharmaceutical solutions market. The new release emphasizes three key enhancements: improved high-throughput PBPK (HT-PBPK) simulations integrated with an AI-driven drug design (AIDD) engine for faster decision-making; an expanded suite of more accurate ADMET models developed with updated AI and premium datasets; and enterprise-level automation features including extended APIs and Python scripting support for better scalability in R&D workflows. This launch, which carries a strongly positive sentiment score of 0.75, aims to solidify ADMET Predictor's position as a standard modeling platform by making predictions more accurate and accessible. While Simulations Plus has over 25 years of experience and highlights its early adoption of AI/ML, the company also includes standard forward-looking statements that caution actual results could differ due to risks such as the integration of its ALI and MC business units, meeting financial guidance, maintaining competitive advantages, customer acceptance of new software, general pharmaceutical industry economics, and macroeconomic factors. The market impact score of 0.45 suggests a moderate but noteworthy influence from this announcement.

Key Decisions for Investors

• Investors should view the launch of ADMET Predictor 13 as a positive catalyst that could enhance SLP's revenue streams and market share in the competitive cheminformatics and biosimulation space, driven by its advanced AI/ML capabilities.
• Monitor key performance indicators such as customer adoption rates for ADMET Predictor 13 and its contribution to SLP's financial results, particularly in relation to the company's expectations for the second half of 2025 and fiscal year 2025.
• Carefully consider the disclosed risk factors, including the integration of acquired businesses and broader market conditions, which may impact SLP's ability to fully capitalize on this product launch and achieve its anticipated projections.